[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100502612":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":39,"responsibleParty":57,"collaborators":25,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":65,"eligibilityCriteria":66,"healthyVolunteers":61,"sex":67,"minAge":68,"maxAge":25,"enrollmentInfo":69,"targetDuration":25,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":25,"overallStatus":41,"whyStopped":25,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"CT-derived FFR guided-ITS group","EXPERIMENTAL","CT-derived FFR≤0.8; ITS plus OMT",[13],"Other: ITS plus OMT",{"label":15,"type":16,"description":17,"interventionNames":18},"Medical therapy group","ACTIVE_COMPARATOR","CT-derived FFR≤0.8; OMT alone",[19],"Other: OMT",[21,26],{"type":6,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"ITS plus OMT","Invasive treatment strategy plus optimal medical therapy",[9],null,{"type":6,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"OMT","Optimal medical therapy alone",[15],[31],{"name":32,"affiliation":5,"role":33},"Jian'an Wang, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","+(86)(571) 87784808","wangjianan111@zju.edu.cn",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Hangzhou","Zhejiang","310009","China","CN",{"type":48,"coordinates":49},"Point",[50,51],120.16142,30.29365,{"lat":51,"lon":50},[54],{"name":55,"role":36,"phone":25,"phoneExt":25,"email":56},"Jun Jiang, MD","jiang-jun@zju.edu.cn",{"type":58,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100502612","coronary-ct-derived-ffr-guided-strategy-versus-medical-therapy-100502612",false,"NCT05824520","Coronary CT-Derived FFR-Guided Strategy Versus Medical Therapy","Coronary Computed Tomography-Derived Fraction Flow Reserve (FFR)-Guided Invasive Treatment Strategy (ITS) Versus Optimal Medical Therapy (OMT) Alone in Patient With Chronic Coronary Syndrome","ACCURATE II","Inclusion Criteria:\n\n* Age ≥ 18 years, with at least one vessel has CT-derived FFR≤0.80\n* Patients with chronic coronary syndromes\n* Signed written informed consent\n\nExclusion Criteria:\n\n* The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin, Aspirin, Clopidogrel, Prasugrel, Ticagrelor, Contrast media (Patients with documented sensitivity to contrast media which can be effectively pre-medicated with steroids and diphenhydramine \\[e.g. rash\\] may be enrolled)\n* Prior percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG)\n* Sinus arrhythmia, cardiogenic shock, or severe heart failure (NYHA≥III)\n* Inability or unwillingness to undergo CT scan or coronary angiography\n* Patients on hemodialysis or with severe hepatic or renal insufficiency\n* Left main coronary artery stenosis ≥ 50%\n* Target vessel total occlusion\n* Pregnancy or intention to become pregnant during the course of the trial\n* Patients with a life expectancy less than 2 years","ALL","18 Years",{"count":70,"type":71},1066,"ESTIMATED","INTERVENTIONAL",[74],"NA","The overall purpose of ACCURATE II trial is to compare the clinical outcomes of CT-derived FFR guided strategy versus medical therapy in patients with chronic coronary syndrome.",[77,78],"Coronary Artery Disease","Myocardial Ischaemia","2026-01-29",{"date":81,"type":82},"2026-02-02","ACTUAL",{"date":84,"type":82},"2024-10-10",{"date":86,"type":71},"2032-10-20",{"name":5,"class":6},1]